Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Urogen Pharma Ltd
(NQ:
URGN
)
12.81
-0.25 (-1.91%)
Streaming Delayed Price
Updated: 2:27 PM EDT, Sep 25, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
209,161
Open
13.02
Bid (Size)
12.81 (6)
Ask (Size)
12.85 (3)
Prev. Close
13.06
Today's Range
12.71 - 13.15
52wk Range
10.60 - 20.70
Shares Outstanding
36,130,121
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
UroGen Receives New U.S. Patent Allowance for Next-Generation Mitomycin-Based Products Expected to Provide Protection Until December 2041
September 16, 2024
From
UroGen Pharma Ltd.
Via
Business Wire
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 05, 2024
From
UroGen Pharma Ltd.
Via
Business Wire
Performance
YTD
-15.78%
-15.78%
1 Month
-10.36%
-10.36%
3 Month
-22.32%
-22.32%
6 Month
-15.56%
-15.56%
1 Year
-18.98%
-18.98%
More News
Read More
UroGen Pharma to Present at Upcoming Investor Conferences
August 29, 2024
From
UroGen Pharma Ltd.
Via
Business Wire
UroGen Submits Completed UGN-102 NDA Seeking Approval as the First FDA-Approved Treatment for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
August 14, 2024
From
UroGen Pharma Ltd.
Via
Business Wire
UroGen Catapults On 'Unprecedented' Results For Gel-Based Cancer Drug
June 13, 2024
Via
Investor's Business Daily
URGN Stock Earnings: UroGen Pharma Misses EPS, Misses Revenue for Q2 2024
August 13, 2024
Via
InvestorPlace
UroGen Pharma Ahead of Schedule to Complete UGN-102 NDA Submission and Reports 2024 Second Quarter Financial Results and Business Highlights
August 13, 2024
From
UroGen Pharma Ltd.
Via
Business Wire
UroGen Pharma to Report Second Quarter 2024 Financial Results on Tuesday, August 13, 2024
August 05, 2024
From
UroGen Pharma Ltd.
Via
Business Wire
UroGen Pharma Stock Earns 91 RS Rating
June 27, 2024
Via
Investor's Business Daily
NextEra Energy, Lennar And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
June 18, 2024
Via
Benzinga
UroGen Pharma Announces Pricing of Public Offering of Ordinary Shares and Pre-Funded Warrants
June 17, 2024
From
UroGen Pharma Ltd.
Via
Business Wire
Hasbro, Tutor Perini, Arm Holdings And Other Big Stocks Moving Higher On Friday
June 14, 2024
Via
Benzinga
Hasbro To Rally Around 38%? Here Are 10 Top Analyst Forecasts For Friday
June 14, 2024
Via
Benzinga
UroGen Announces Unprecedented 82.3% Duration of Response at 12 Months in the ENVISION Trial Investigating UGN-102 as Potentially the First FDA-Approved Non-Surgical Treatment for LG-IR-NMIBC
June 13, 2024
From
UroGen Pharma Ltd.
Via
Business Wire
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 07, 2024
From
UroGen Pharma Ltd.
Via
Business Wire
UroGen Pharma to Host UGN-102 Virtual Data Event on June 13, 2024
June 06, 2024
From
UroGen Pharma Ltd.
Via
Business Wire
UroGen Pharma to Present at the 45th Annual Goldman Sachs Global Healthcare Conference
June 05, 2024
From
UroGen Pharma Ltd.
Via
Business Wire
UroGen Pharma Appoints David Lin as New Chief Commercial Officer
June 03, 2024
From
UroGen Pharma Ltd.
Via
Business Wire
UroGen Pharma to Present at the TD Cowen 5th Annual Oncology Innovation Summit
May 22, 2024
From
UroGen Pharma Ltd.
Via
Business Wire
URGN Stock Earnings: UroGen Pharma Misses EPS, Misses Revenue for Q1 2024
May 13, 2024
Via
InvestorPlace
UroGen Pharma Announces Date for ENVISION Data, New Long-Term Jelmyto Durability Data, and Reports 2024 First Quarter Financial Results and Business Highlights
May 13, 2024
From
UroGen Pharma Ltd.
Via
Business Wire
UroGen Pharma to Participate at Upcoming Investor Conferences
May 07, 2024
From
UroGen Pharma Ltd.
Via
Business Wire
New Real-World Retrospective Analysis Presented at AUA 2024 Reports 86% Recurrence-Free Survival (RFS) at 24 Months with JELMYTO® Across All Studied Patient and Disease Characteristics in Cohort of Responders to Induction Therapy
May 05, 2024
From
UroGen Pharma Ltd.
Via
Business Wire
UroGen Announces Results from ATLAS Showing Robust UGN-102 Durability of Response in New and Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer at AUA 2024
May 04, 2024
From
UroGen Pharma Ltd.
Via
Business Wire
New Real-World Study on Retrograde Instillation of JELMYTO® for Treatment of Low-Grade Upper Tract Urothelial Cancer Reports Similar Complete Response Rate and Lower Stricture Rate Compared to OLYMPUS Pivotal Trial
May 04, 2024
From
UroGen Pharma Ltd.
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.